Kiniksa Pharmaceuticals, Ltd.

NasdaqGS:KNSA Stock Report

Market Cap: US$1.4b

Kiniksa Pharmaceuticals Dividend

Dividend criteria checks 0/6

Kiniksa Pharmaceuticals does not have a record of paying a dividend.

Key information

n/a

Dividend yield

n/a

Payout ratio

Industry average yield2.7%
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Earnings per shareUS$0.20
Dividend yield forecast in 3Y0%

Recent dividend updates

No updates

Recent updates

Kiniksa Pharmaceuticals, Ltd. Just Reported A Surprise Profit And Analysts Updated Their Estimates

Mar 01
Kiniksa Pharmaceuticals, Ltd. Just Reported A Surprise Profit And Analysts Updated Their Estimates

We're Not Worried About Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn

Feb 28
We're Not Worried About Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn

The Market Doesn't Like What It Sees From Kiniksa Pharmaceuticals, Ltd.'s (NASDAQ:KNSA) Revenues Yet

Dec 18
The Market Doesn't Like What It Sees From Kiniksa Pharmaceuticals, Ltd.'s (NASDAQ:KNSA) Revenues Yet

We're Interested To See How Kiniksa Pharmaceuticals (NASDAQ:KNSA) Uses Its Cash Hoard To Grow

Nov 10
We're Interested To See How Kiniksa Pharmaceuticals (NASDAQ:KNSA) Uses Its Cash Hoard To Grow

Investors Don't See Light At End Of Kiniksa Pharmaceuticals, Ltd.'s (NASDAQ:KNSA) Tunnel

Apr 18
Investors Don't See Light At End Of Kiniksa Pharmaceuticals, Ltd.'s (NASDAQ:KNSA) Tunnel

Investors Shouldn't Be Too Comfortable With Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Robust Earnings

Nov 10
Investors Shouldn't Be Too Comfortable With Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Robust Earnings

Industry Analysts Just Upgraded Their Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Revenue Forecasts By 27%

Aug 04
Industry Analysts Just Upgraded Their Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Revenue Forecasts By 27%

Kiniksa Pharmaceuticals GAAP EPS of -$0.29 beats by $0.15, revenue of $26.97M misses by $1.58M, reaffirms FY revenue guidance

Aug 03

Analysts Are Updating Their Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Estimates After Its First-Quarter Results

May 05
Analysts Are Updating Their Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Estimates After Its First-Quarter Results

We're Keeping An Eye On Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Rate

Mar 18
We're Keeping An Eye On Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Rate

Kiniksa: Latest Earnings Beat Shows Light At The End Of The Tunnel

Nov 25

Is Kiniksa Pharmaceuticals (NASDAQ:KNSA) A Risky Investment?

Nov 04
Is Kiniksa Pharmaceuticals (NASDAQ:KNSA) A Risky Investment?

Kiniksa: Unexciting, Slow Growth Stock

Aug 13

We're Keeping An Eye On Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Rate

Jul 31
We're Keeping An Eye On Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Rate

Kiniksa outlines development path for mavrilimumab after FDA feedback

Jun 08

Kiniksa: A Look At Mavrilimumab

May 03

Here's Why We're Not Too Worried About Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Situation

Apr 17
Here's Why We're Not Too Worried About Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Situation

What Kind Of Investors Own Most Of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)?

Jan 02
What Kind Of Investors Own Most Of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)?

Kiniksa's antibody treatment shows clinical benefit in late-stage COVID-19 study

Dec 22

Dosing underway in Kiniksa Pharma's lumpy skin disease study with vixarelimab

Dec 15

Kiniksa Pharma's KPL-404 shows encouraging action in early-stage study

Nov 30

Kiniksa's vixarelimab nabs accelerated review in U.S. for a skin disorder

Nov 16

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if KNSA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if KNSA's dividend payments have been increasing.


Dividend Yield vs Market

Kiniksa Pharmaceuticals Dividend Yield vs Market
How does KNSA dividend yield compare to the market?
SegmentDividend Yield
Company (KNSA)n/a
Market Bottom 25% (US)1.5%
Market Top 25% (US)4.7%
Industry Average (Biotechs)2.7%
Analyst forecast in 3 Years (KNSA)0%

Notable Dividend: Unable to evaluate KNSA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate KNSA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate KNSA's payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as KNSA has not reported any payouts.


Discover strong dividend paying companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.